Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 4/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21923115 | 0.80 | LOX (0.49) | ENPP2GRM5GAAPDE2AAAK1 | |
| SCHEMBL21923110 | 0.80 | GABRG2 (0.46) | ENPP2GRM5 | |
| SCHEMBL21922389 | 0.76 | ENPP2 (0.46) | ENPP2GRM5PDCD1CD274 | |
| SCHEMBL21922387 | 0.73 | ENPP2 (0.51) | ENPP2GRM5 | |
| SCHEMBL21922352 | 0.73 | GAA (0.53) | GAA | |
| SCHEMBL1145730 | 0.73 | GRM5 (0.41) | ENPP2GRM5PRKDCPDCD1CD274 | |
| SCHEMBL26581171 | 0.71 | MAOB (0.41) | GAA | |
| SCHEMBL4016988 | 0.70 | GRM5 (0.38) | ENPP2GRM5PRKDCPDCD1CD274 | |
| SCHEMBL5983583 | 0.70 | AAK1 (0.40) | AAK1PRMT5WDR77 | |
| SCHEMBL1145726 | 0.70 | GRM5 (0.39) | ENPP2GRM5PRKDCPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131151-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131151-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | ENPP2 1/4885GRM5 1894/4885PRKDC 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.